within Pharmacolibrary.Drugs.ATC.N;

model N05BX02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 5.833333333333333e-06,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011666666666666665,
    Tlag           = 600,            
    Vdp             = 0.0025,
    k12             = 0.18,
    k21             = 0.18
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05BX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Gedocarnil is an antipsychotic drug belonging to the benzamide class. It was investigated for the treatment of schizophrenia and other psychotic disorders but is not currently approved or marketed for therapeutic use.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic studies with reported parameters found for gedocarnil in the literature as of June 2024. All values below are estimates based on similar atypical antipsychotic agents.</p><h4>References</h4><ol><li><p>Atkinson, HC, et al., &amp; Robson, R (2015). Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. <i>Clinical drug investigation</i> 35(10) 625–632. DOI:<a href=\"https://doi.org/10.1007/s40261-015-0320-8\">10.1007/s40261-015-0320-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26334726/\">https://pubmed.ncbi.nlm.nih.gov/26334726</a></p></li><li><p>Freedman, MD, &amp; Somberg, JC (1991). Pharmacology and pharmacokinetics of amiodarone. <i>Journal of clinical pharmacology</i> 31(11) 1061–1069. DOI:<a href=\"https://doi.org/10.1002/j.1552-4604.1991.tb03673.x\">10.1002/j.1552-4604.1991.tb03673.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1753010/\">https://pubmed.ncbi.nlm.nih.gov/1753010</a></p></li><li><p>Chryssafidis, P, et al., &amp; Macheras, P (2021). Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations. <i>Pharmaceutical research</i> 38(8) 1345–1356. DOI:<a href=\"https://doi.org/10.1007/s11095-021-03078-w\">10.1007/s11095-021-03078-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34341958/\">https://pubmed.ncbi.nlm.nih.gov/34341958</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05BX02;
